Salarius Shares Plunge 50% After Merger Reveal with Decoy Therapeutics

Introduction to SALARIUS PHARMACEUTICALS INC

SALARIUS PHARMACEUTICALS INC (NASDAQ: SLRX) is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. As of 2025-11-11, the stock closed at USD 0.9899, reflecting a 50.51% decline for the trading session, on a volume of 1,617,491 shares. The company develops therapies aimed at correcting dysregulated gene expression in cancer cells through targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs).

Corporate Structure and Experience

Founded in 2011, Salarius employs between 11 and 50 staff members. Key personnel include Chief Executive Officer David Arthur and Chief Operating Officer Tess Burleson, CPA, MBA. The Board of Directors is chaired by William McVicar, PhD. Salarius operates from the Texas Medical Center Innovation facility and collaborates with academic institutions such as the MD Anderson Cancer Center.

Biopharmaceuticals by little plant

Developments and News

• 2025-11-10: Salarius filed a free writing prospectus (FWP) disclosing a definitive merger agreement with Decoy Therapeutics. The transaction is structured as a stock-for-stock exchange, resulting in pro forma ownership of approximately 85.2% for Decoy and 14.8% for Salarius. Completion is contingent on securing at least USD 6.0 million in proceeds and maintaining NASDAQ listing standards.
• 2025-11-07: Proxy materials (DEF 14A) were filed concerning the transaction and corporate governance matters.
• Fall 2023: The lead TPD candidate, SP-3164, entered IND-enabling studies with plans for a first-in-human trial by year-end.
• 2021: Interim Phase 1/2 data for the LSD1 inhibitor seclidemstat (SP-2577) in Ewing sarcoma indicated tolerable dosing and preliminary signs of activity.
• Recognition: Salarius received a USD 16.1 million Cancer Prevention and Research Institute of Texas (CPRIT) Product Development Award and financial support from the National Pediatric Cancer Foundation.

Financial and Strategic Analysis

At USD 0.9899 per share, Salarius’s market capitalization is approximately USD 1.0 million. Key financial metrics (TTM) include:

• Net income: –USD 5.1 million
• Diluted EPS: –23.70
• Total cash: USD 794,890
• Levered free cash flow: –USD 2.66 million

The company secured USD 6.5 million in non-dilutive funding to support its pipeline. Strategic initiatives center on two modalities:

1. TPIs, led by seclidemstat (SP-2577), targeting Ewing sarcoma (Phase 1/2) and hematologic malignancies (MDS/CMML trial at MD Anderson).
2. TPDs, led by SP-3164, a deuterium-enabled molecular glue designed to degrade transcription factors IKZF1 and IKZF3, with clinical evaluation expected to begin in late 2023.

The merger with Decoy Therapeutics aims to combine peptide-conjugate platforms and enhance antiviral drug development through the IM-P3ACT system.

Market Position and Industry Context

Salarius operates in the oncology segment of clinical-stage biopharmaceuticals, focusing on epigenetic therapies. Seclidemstat holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. FDA for Ewing sarcoma. The company competes with other oncology developers of epigenetic and protein degradation therapeutics. With a 52-week trading range of USD 0.91–108.00, its share price volatility reflects development milestones and funding requirements. Average daily volume over 10 trading sessions stands near 275,157 shares, indicating liquidity relative to peers.

tl;dr

On 2025-11-10, Salarius disclosed a merger agreement with Decoy Therapeutics, requiring USD 6.0 million in proceeds and NASDAQ compliance for closing. The stock declined 50.51% to USD 0.9899 on 2025-11-11. The company holds USD 794,890 in cash and reports negative free cash flow of USD 2.66 million (TTM). Seclidemstat is in Phase 1/2 trials, while SP-3164 is poised to enter first-in-human studies by year-end 2023. Future outlook depends on merger completion, trial outcomes, and additional financing.